ommend that they undergo irradiation of the high axilla and SCF for adjuvant care, if they do not undergo complete axillary dissection.
INTRODUCTION
The standard treatment for patients with a positive sentinel lymph node (SLN) is complete level I-II axillary lymph node dissection (ALND). However, for various reasons, some node-positive patients are referred for adjuvant radiotherapy without undergoing axillary dissection.
The appropriate treatment for these patients is currently unclear. In these circumstances, some radiation oncologists include a portion of levels I and II of the axilla in the standard tangential fields and they treat the breast after lumpectomy or local excision by extending the cranial border of these fields to near the humeral head. This technique can include >80% of the axillary level I and II lymph nodes.(7) Alternatively, others comprehensively treat these patients with a third anterior field to encompass the axillary apex and SCF, with or without a posterior boost field at the mid-axilla. Yet irradiating the high axilla and SCF has been shown to increase the treatment morbidity, including causing pneumonitis, lymphedema, brachial plexopathy and significant shoulder-joint dysfunction. (8) (9) (10) Radiation oncologists are faced with the Purpose: We evaluate the predictors of 4 or more involved axillary nodes in patients with node-positive T1-2 breast carcinoma to select a group of patients who are indicated for adjuvant irradiation of the level III axilla and supraclavicular fossa (SCF). Methods: We analyzed 286 patients with positive axillary nodes and who were without distant metastases and who underwent breast conserving surgery and axillary lymph node dissection or modified radical mastectomy. We investigated the relationship between the patients and the tumor factors and 4 or more positive axillary nodes. Results: On the multivariate logistic-regression analysis, an increased tumor size (p=0.002), the presence of lymphovascular space invasion (LVSI) (p<0.001) and a palpable mass p<0.001) were positively associated with involvement of 4 or more axillary lymph nodes. In our study, 86.1% of the patients with all the unfavorable factors had involvement of 4 or more nodal metastases. Conclusion: Our data suggest that for patients with node-positive T1-2 breast cancer, the presence of 4 or more involved nodes is frequently observed for the patients with an increased tumor size, the presence of LVSI and a palpable mass at the time of diagnosis, and we recchallenge of designing radiation fields that treat the nodal area at risk, while minimizing the volume of the irradiated normal tissue. The purpose of this study was to evaluate the predictors of 4 or more involved axillary nodes in patients with node-positive T1-2 breast carcinoma to select a group of patients who require adjuvant irradiation of the level III axilla and SCF. 
METHODS

Patient and tumor characteristics
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RESULTS
The patient and tumor characteristics are listed in Table 1 . The median age of the included patients who were treated with surgery was 48 yr (range, 29-75 yr).
The majority of the patients included in this study were Koreans (94%). Most of the tumors were T2 tumors (62.9 %), and most of the patients had palpable masses at the time of diagnosis (79%).
The predominant tumor type was invasive ductal carcinoma (87%), followed by medullary carcinoma (6%). Positive LVSI was identified in 37.1% of the tumors. Of the patients included in this study, 59.1% were ER-positive, 59.5%
were PR-positive and 72.0% were HER2-negative.
Potential predictors of 4 or more involved nodes
Of the 286 patients, 130 had 4 or more involved axillary
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Another weak point of our study is that we have reported that 40.6% of the patients' histologic grade and 43.0% of the patients' EGFR status were unavailable for analysis.
However, we found a preoperative clinical factor, that is, tumor palpability, to be a prognostic factor for 4 or more involved axillary nodes, and our study is still worthy.
For the patients with all the favorable factors such as a lack of LVSI, a nonpalpable mass and T1 tumor, and only a small percentage of these patients (10%) have 4 or more nodal metastases, irradiation of the high axilla and SCF would be overtreating almost 90% of these patients. However, for the patients who have all the unfavorable factors, and 86.1% of these patients have 4 or more nodal metastases, adjuvant irradiation of the high axilla and SCF is strongly justified and it should be carried out if they do not undergo complete ALND.
CONCLUSION
Our data suggests that for the patients with node-positive T1-2 breast cancer, the presence of 4 or more involved nodes is frequently seen for the patients with an increased tumor size, the presence of LVSI and a palpable mass at the time of diagnosis, and we recommend that these patients receive irradiation of the high axilla and SCF for adjuvant care, if they do not undergo complete axillary dissection.
